Three Or More Ring Hetero Atoms In The Bicyclo Ring System Patents (Class 544/350)
  • Patent number: 11117894
    Abstract: Disclosed herein, inter alia, are pyridopyrazines and methods of using the same.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: September 14, 2021
    Assignees: City of Hope, National and Kapodistrian University of Athens
    Inventors: Sangkil Nam, David Horne, Ravi Salgia, Alexios-Leandros Skaltsounis, Nikolaos Lougiakis, Nicole Pouli, Panagiotis Marakos
  • Patent number: 11077107
    Abstract: Disclosed are compounds of the formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: August 3, 2021
    Inventors: Harald Engelhardt, Davide Gianni, Christian Smethurst
  • Patent number: 11015216
    Abstract: Described are substituted imidazo[1,2-a]pyrazine compounds, which are coelenterazine analogues, kits comprising the compounds, and methods of using the compounds for the detection of luminescence in luciferase-based assays. Also described are methods of making the compounds, such as a method using aminopyrazine acetophosphonates as synthesis intermediates.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: May 25, 2021
    Assignee: PROMEGA CORPORATION
    Inventors: Anton Shakhmin, Thomas Kirkland, Joel Walker, Thomas Machleidt, Mary Hall, Keith V. Wood
  • Patent number: 10899767
    Abstract: Crystalline forms of ACP-196, preparation methods, pharmaceutical compositions and uses thereof in the preparation of drugs for treatment and/or prevention of Bruton's tyrosine kinase (BTK)-mediated disorders such as autoimmune diseases or disorders, heteroimmune diseases or disorders, cancers including lymphoma and inflammatory diseases or disorders. As compared with the known solid form of ACP-196, the crystalline forms of the present invention have advantages in crystallinity.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: January 26, 2021
    Assignee: Hangzhou SoliPharma Co., Ltd.
    Inventors: Xiaohong Sheng, Xiaoxia Sheng, Tao Zhu
  • Patent number: 10836768
    Abstract: A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: November 17, 2020
    Assignee: Ogeda SA
    Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
  • Patent number: 10800787
    Abstract: The present invention provides processes for the preparation of Acalabrutinib (1), as well as intermediates useful in the preparation thereof. In particular, processes are provided for coupling of a compound of Formula (5) and 2-butynoic acid in the presence of Carbodiimide (8) to afford Acalabrutinib (1).
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: October 13, 2020
    Assignee: Apotex Inc.
    Inventors: Prabhudas Bodhuri, Boris Gorin, Melanie R. A. Green, Gamini Weeratunga
  • Patent number: 10766899
    Abstract: Provided are methods of preparing compounds of Formula 201:
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: September 8, 2020
    Assignee: CYTOKINETICS, INCORPORATED
    Inventors: Bradley P. Morgan, David J. Morgans, Jr., Alex Muci
  • Patent number: 10738046
    Abstract: The present invention provides compounds of formula I: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: August 7, 2018
    Date of Patent: August 11, 2020
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • Patent number: 10683298
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: November 12, 2018
    Date of Patent: June 16, 2020
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
  • Patent number: 10669568
    Abstract: Described are substituted imidazo[1,2-a]pyrazine compounds, which are coelenterazine analogues, kits comprising the compounds, and methods of using the compounds for the detection of luminescence in luciferase-based assays. Also described are methods from making the compounds, such as a method using aminopyrazine acetophosphonates as synthesis intermediates.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: June 2, 2020
    Assignee: PROMEGA CORPORATION
    Inventors: Anton Shakhmin, Thomas Kirkland, Joel Walker, Thomas Machleidt, Mary Hall, Keith V. Wood
  • Patent number: 10584129
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: March 10, 2020
    Assignee: Janssen Pharmaceuticals NV
    Inventors: Sergio-Alvar Alonso-de Diego, José Maria Cid-Núñez, Óscar Delgado-González, Annelies Marie Antonius Decorte, Michiel Luc Maria Van Gool, Gregor James MacDonald, Antonius Adrianus Hendrikus Petrus Megens, Andrés Avelino Trabanco-Suárez, Aránzazu García-Molina, José Ignacio Andrés-Gil
  • Patent number: 10577370
    Abstract: Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: March 3, 2020
    Assignee: PROMEGA CORPORATION
    Inventors: Mary Hall, Thomas Kirkland, Poncho Meisenheimer, Rachel Friedman Ohana, Anton Shakhmin, Joel R. Walker, Wenhui Zhou
  • Patent number: 10556908
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 11, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • Patent number: 10406157
    Abstract: Disclosed is a compound of Formula 1, and a pharmaceutically acceptable salt thereof. This disclosure also relates to materials and methods for preparing the compound of Formula 1, to pharmaceutical compositions which contain it, and to its use for treating diseases, disorders, and conditions associated with GPR6.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: September 10, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • Patent number: 10328074
    Abstract: Method for treating AML and MM by administration of a compound of the formula (I) wherein the groups R1 to R3 have the meanings given in the specification.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: June 25, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Davide Gianni, Christian Smethurst
  • Patent number: 10280447
    Abstract: Described are substituted imidazo[1,2-a]pyrazine compounds of formula (I), which are coelenterazine analogs, methods for making the compounds, kits comprising the compounds, and methods of using the compounds for the detection of luminescence in luciferase-based assays.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: May 7, 2019
    Assignee: Promega Corporation
    Inventors: Mary Hall, Thomas Kirkland, Thomas Machleidt, Anton Shakhmin, Joel R. Walker, Keith V. Wood, Wenhui Zhou
  • Patent number: 10280170
    Abstract: The present invention relates to substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives of formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as ROS1 inhibitors. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: May 7, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Laurence Anne Mevellec, Elisabeth Therese Jeanne Pasquier, Sophie Descamps, Guillaume Jean Maurice Mercey, Berthold Wroblowski, Jorge Eduardo Vialard, Lieven Meerpoel, Matthieu Ludovic Jeanty, Thierry Francois Alain Jean Jousseaume
  • Patent number: 10214533
    Abstract: Novel compounds of Formula I and their use in therapeutic treatments.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: February 26, 2019
    Assignee: OGEDA SA
    Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
  • Patent number: 10183948
    Abstract: A method for treating and/or preventing polycystic ovary syndrome (PCOS) including the administration, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: January 22, 2019
    Assignee: OGEDA SA
    Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
  • Patent number: 10167282
    Abstract: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea compounds (referred herein as “TBAP compounds”) that, inter alia, inhibit RAF (e.g., BRAF, CRAF, etc.). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit RAF (e.g., BRAF, CRAF, etc.); and to treat disorders including: proliferative disorders; cancer (including, e.g., malignant melanoma, colorectal carcinoma, pancreatic adenocarcinoma); inflammation; immunological disorders; viral infections; fibrotic disorders; disorders associated with a mutated form of RAF (e.g., BRAF, CRAF, etc.); disorders ameliorated by the inhibition of RAF (e.g., BRAF, CRAF, etc.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: January 1, 2019
    Assignees: CANCER RESEARCH TECHNOLOGY LIMITED, INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)
    Inventors: Caroline Joy Springer, Richard Marais, Romina Girotti, Dan Niculescu-Duvaz, Ion Niculescu-Duvaz, Alfonso Zambon
  • Patent number: 10167290
    Abstract: Provided herein are methods for the preparation of substituted pyrazino[2,3-b]pyrazines of the formula (II): the method comprising contacting a compound of formula (VI): with R1—Y in a solvent, in the presence of a palladium catalyst, wherein said contacting occurs in the presence of a base, wherein R1-R3, Y, the palladium catalyst and the base are as defined herein.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: January 1, 2019
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
  • Patent number: 10138248
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: November 27, 2018
    Assignee: Incyte Corporation
    Inventors: Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue
  • Patent number: 10125133
    Abstract: The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: November 13, 2018
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
  • Patent number: 10112950
    Abstract: The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: October 30, 2018
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Joel R. Courter, Chunhong He, Jingwei Li, Liang Lu, Yaping Sun, Xiaozhao Wang, Wenqing Yao, Colin Zhang, Jincong Zhuo
  • Patent number: 10100053
    Abstract: The present invention pertains generally to the field of organic chemical synthesis, and in particular to certain methods for the synthesis of 8-(4-aminophenyoxy)-4H-pyrido[2,3-b]pyrazin-3-one and related compounds (denoted herein as (3)) from 4-(4-aminophenyoxy)pyridine-2,3-diamine and related compounds (denoted herein as (1)), by reaction with glyoxylic acid (denoted herein as (2)). The compounds (3) are useful in the synthesis of known anti-cancer agents, such as 1-(5-tert-butyl-2-(4-methyl-phenyl)-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4H-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: October 16, 2018
    Assignees: Cancer Research Technology Limited, Institute of Cancer Research: Royal Cancer Hosp. (The)
    Inventors: Alfonso Zambon, Dan Niculescu-Duvaz, Richard Chubb, Caroline Joy Springer
  • Patent number: 10045982
    Abstract: The invention relates to new pyridopyrazine derivative compounds of formula (I-A) or formula (I-B): to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: August 14, 2018
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Valerio Berdini, Gordon Saxty, Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Bruno Roux, Lieven Meerpoel
  • Patent number: 10047092
    Abstract: The present invention is directed to a compound of Formula (I) and to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: August 14, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Jason C. Rech, Brad M. Savall
  • Patent number: 10039766
    Abstract: The present invention discloses certain new solid state forms of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: August 7, 2018
    Assignee: AstraZeneca AB
    Inventor: Gary Peter Tomkinson
  • Patent number: 10030025
    Abstract: Novel compounds of Formula I and their use in therapeutic treatments.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: July 24, 2018
    Assignee: OGEDA SA
    Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
  • Patent number: 10017514
    Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: July 10, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Susana Conde-Ceide, Michiel Luc Maria Van Gool, Maria Luz Martin-Martin
  • Patent number: 10004735
    Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: June 26, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Kimberly Elizabeth Fultz, Tam Minh Tran, Shuichan Xu, Weiming Xu
  • Patent number: 10004733
    Abstract: The invention relates to new pyridopyrazine derivative compounds of formula (I-A) or formula (I-B): to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 26, 2018
    Assignee: ASTEX THERAPEUTICS LTD
    Inventors: Valerio Berdini, Gordon Saxty, Patrick Rene Angibaud, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Bruno Roux, Lieven Meerpoel
  • Patent number: 9987274
    Abstract: A method for treating and/or preventing hot flashes, by administering, to a patient in need thereof, of a pharmaceutically effective amount of a compound of Formula I or a pharmaceutically acceptable solvate thereof.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: June 5, 2018
    Assignee: OGEDA SA
    Inventors: Hamid Hoveyda, Guillaume Dutheuil, Graeme Fraser
  • Patent number: 9981971
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to the Compound for formula 1: having the name 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and tautomers thereof.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: May 29, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventor: Nathan Boersen
  • Patent number: 9975898
    Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to the compound of formula (I): having the name 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and tautomers thereof.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: May 22, 2018
    Assignee: Signal Pharmaceuticals, LLC
    Inventor: Jeffrey Eckert
  • Patent number: 9968601
    Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: May 15, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Jeffrey E. Kropf, Seung H. Lee, Jennifer R. Lo, Scott A. Mitchell, Aaron C. Schmitt, Sundaramoorthi Swaminathan, Jin-Ming Xiong, Jianjun Xu, Zhongdong Zhao
  • Patent number: 9956218
    Abstract: Provided are certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: May 1, 2018
    Assignee: Hutchison Medipharma Limited
    Inventors: Wei-Guo Su, Hong Jia, Guangxiu Dai
  • Patent number: 9938564
    Abstract: The present invention provides, among other things, imidazo[1,2-?]pyrazine derivatives including The derivatives are useful in any method which other coelenterazines have been used. For example, the derivatives may be used in a bioluminogenic method to detect the presence of certain compounds or molecules.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: April 10, 2018
    Assignee: PROMEGA CORPORATION
    Inventors: Dieter H. Klaubert, Poncho Meisenheimer, James Unch
  • Patent number: 9771371
    Abstract: Provided herein are Heteroaryl Compounds having the following structure: wherein R1-R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: September 26, 2017
    Assignee: Signal Pharmaceuticals, LLC
    Inventors: Jan Elsner, Roy L. Harris, Branden Gingsee Lee, Deborah Mortensen, Garrick K. Packard, Patrick Papa, Jason Parnes, Sophie Perrin-Ninkovic, Jennifer Riggs, John Sapienza, Graziella I. Shevlin, Lida Tehrani, Jingjing Zhao
  • Patent number: 9745309
    Abstract: The present invention provides a method for preparing an intermediate compound of sitagliptin represented by formula I. The preparation method comprises: dissolving a compound represented by formula II into an organic solvent; and under the catalysis of fatty acid and effect of chlorosilane, performing a reduction reaction of carbon-carbon double bonds, so as to obtain the intermediate compound of sitagliptin represented by formula I, R being methyl or formoxyl. The preparation method of the present invention avoids precious metal as a catalyst, and accordingly, the cost is low, the post-treatment is simple, the product has a high yield, chemical purity and optical purity, and de % is greater than 99.6%, and the preparation method can be used in synthesis of sitagliptin and is suitable for industrial production.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: August 29, 2017
    Assignees: Shanghai Institute of Pharmaceutical Industry, Zhejiang Medicine Co., Ltd.
    Inventors: Kuaile Lin, Zhengyan Cai, Jing Pan, Weicheng Zhou, Guofeng Wu, Lirong Yue, Dadong Shen
  • Patent number: 9708313
    Abstract: This present invention provides compounds of formula II: which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: July 18, 2017
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
  • Patent number: 9669029
    Abstract: This invention is directed to compounds, which are PDE10A enzyme inhibitors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The present invention also provides processes for the preparation of the compounds of formula I. The present invention further provides a method of treating a subject suffering from a neurodegenerative disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention also provides a method of treating a subject suffering from a drug addiction comprising administering to the subject a therapeutically effective amount of a compound of formula I. The present invention further provides a method of treating a subject suffering from a psychiatric disorder comprising administering to the subject a therapeutically effective amount of a compound of formula I.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: June 6, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Ask Püschl, Jacob Nielsen, Jan Kehler, John Paul Kilburn, Mauro Marigo, Morten Langgård
  • Patent number: 9645128
    Abstract: There has been a need for coelenterazine analogs that exhibit luminescence properties different from those of known coelenterazine analogs. The present invention provides the compound represented by general formula (1).
    Type: Grant
    Filed: August 14, 2015
    Date of Patent: May 9, 2017
    Assignees: JNC CORPORATION, TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Satoshi Inouye, Yuiko Sahara, Rie Iimori, Takamitsu Hosoya
  • Patent number: 9598442
    Abstract: A crystallized hybrid solid with an organic-inorganic matrix, of three-dimensional structure, containing an inorganic network of zinc-based metal centers connected to one another by organic ligands constituted by the entities —O2C—C6H3—N3—CO2— and C6H12N2. Said solid is called DMOF-1-N3, and has Zn2(—O2C—C6H3—N3—CO2—)2(C6H12N2) for its base pattern.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: March 21, 2017
    Assignees: IFP ENERGIES NOUVELLES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Marie Savonnet, David Farrusseng, Catherine Pinel, Delphine Bazer-Bachi, Nicolas Bats, Vincent Lecocq
  • Patent number: 9592230
    Abstract: This invention is directed to phenylimidazole derivatives having the formula I: wherein HET is an optionally substituted heteroaromatic group; -L- is selected from the group consisting of —CH2—CH2—, —S—CH2—, —CH2—S— and —CH?CH—, R1 is selected from the group consisting of H, C1-C6 alkyl; C1-C6 alkyl(C3-C8)cycloalkyl; C1-C6 hydroxyalkyl, CH2CN, CH2C(O)NH2, C1-C6 arylalkyl, and C1-C6 alkyl-heterocycloalkyl, and R2, R3, R4, R5 and R6 are selected individually from the group consisting of H, C1-C6 alkoxy and halogen, or pharmaceutically acceptable acid addition salts thereof, which are PDE10A enzyme inhibitors useful in the treatment of psychiatric disorders and drug addiction.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: March 14, 2017
    Assignee: H. Lundbeck A/S
    Inventors: Andreas Ritzen, Morten Langgard, Jan Kehler, Jacob Nielsen, John Paul Kilburn, Mohamed M. Farah
  • Patent number: 9527841
    Abstract: The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: December 27, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Shinji Nakamura, Satoshi Mikami, Kawasaki Masanori, Izumi Nomura, Tomoko Ashizawa, Takahiko Taniguchi
  • Patent number: 9487525
    Abstract: The present invention discloses certain new solid state forms of (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide, processes for preparing such forms, pharmaceutical compositions comprising them, and the use of such forms in therapy.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: November 8, 2016
    Assignee: AstraZeneca AB
    Inventor: Gary Peter Tomkinson
  • Patent number: 9409912
    Abstract: The present invention relates to a method for the preparation of sitagliptin phosphate and sitagliptin phosphate anhydrous of Formula (I?) and monohydrate of Formula (I),
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: August 9, 2016
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Shri prakash Dhar Dwivedi, Kumar Kamlesh Singh, Sunil Dnyaneshwar Narode, Dhaval Jashvantbhai Patel, Kirtipalsinh Sajjansinh Solanki
  • Patent number: 9394396
    Abstract: An effective hydrogen sulfide scavenger that produces little corrosion may be prepared by reacting glyoxal with a compound having at least two primary or secondary amine groups. The subject hydrogen sulfide scavengers may be used with both the production of crude oil and natural gas, and the refining of same.
    Type: Grant
    Filed: June 19, 2012
    Date of Patent: July 19, 2016
    Assignee: Baker Hughes Incorporated
    Inventors: Joseph L. Stark, Robert A. Steele, Ksenija Babić-Samard{hacek over (z)}ija, John A. Schield, Weldon J. Cappel, Matthew T. Barnes
  • Patent number: 9315783
    Abstract: There has been a demand for a codon-optimized gene for the mutated catalytic domain of Oplophorus luciferase, which is capable of efficiently expressing a protein both in a cultured animal cell and Escherichia coli. There has also been a demand for a substrate coelenterazine analogue showing a higher activity than that of native 19 kDa protein. The invention provides a polynucleotide comprising a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 2. According to the invention, bis-coelenterazine is used as a substrate coelenterazine analogue suitable for the photoprotein encoded by the polynucleotide comprising the polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 2.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: April 19, 2016
    Assignee: JNC CORPORATION
    Inventors: Satoshi Inouye, Junichi Sato